Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of CP-690,550 maintenance therapy in Crohn's disease
NL-OMON43589Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tofacitinib in Crohn's disease (2 arms), sponsored by Pfizer. Started Nov 2014; status: active, not recruiting.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON43589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43589.